RESILIENT: RandomisEd, controlled, double blind Study to assess mechanistic effects of combination therapy of dapagliflozin with Exenatide QW versus dapagliflozin alone in obese (BMI>30 kg/m2) patients with Type 2 diabetes mellitus
Latest Information Update: 20 Feb 2024
At a glance
- Drugs Dapagliflozin (Primary) ; Exenatide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms RESILIENT - Version 3.0
- 02 Feb 2021 Status changed from active, no longer recruiting to completed.
- 02 Feb 2021 Planned End Date changed from 31 Jan 2019 to 30 Sep 2022.
- 05 Apr 2017 Planned number of patients changed from 111 to 120.